Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Unknown 2Recruiting 1Completed 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Plasma cell 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Multiple Myeloma 1Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × BEBT-908 × Lymphoid × Clear all
NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med Inc

Phase 3 Recruiting
416 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06164327 2023-12-11

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med Inc

Phase 1 Unknown
75 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06082596 2023-10-13

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

BeBetter Med Inc

Phase 1 Completed
32 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT06074107 2023-10-11

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

BeBetter Med Inc

Phase 2 Unknown
128 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡